CVRx Announces Availability of Additional Data Supporting Long-term Benefits of Barostim
DAIC
APRIL 16, 2024
William Abraham of the Ohio State Wexner College of Medicine presented analysis showing that patients in the trial with Barostim + GDMT had a 74% reduced risk of receiving advanced heart failure interventions (transplant, LVAD, CCM, CRT or CardioMEMS) at long-term follow-up versus patients on GDMT alone. See more details at TCTMD.
Let's personalize your content